Reading ANIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIX free→Reading ANIX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIX free→QuarterlyIQ Insights · ANIX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. On February 9, 2026, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that encouraging patient survival data had been observed in its ovarian cancer CAR-T therapy Phase 1 clinical trial and that regulatory approval had been granted enabling dose escalation in the trial beyond the doses set forth in the original trial protocol. The press release is furnished as Exhibit 99.1 hereto Statements that are not historical fact m…
Regulation FD Disclosure. On December 11, 2025, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that the Company and The Cleveland Clinic Foundation (“Cleveland Clinic”) presented final data from the Phase 1 clinical trial of its investigational breast cancer vaccine. The press release, which is furnished as Exhibit 99.1 hereto, was issued following a presentation made by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.